[Bilateral subthalamic nucleus deep-brain stimulation (STN-DBS) in Parkinson's disease: initial experience in Cruces Hospital].
2003; National Institutes of Health; Volume: 18; Issue: 4 Linguagem: Inglês
Autores
E. Lezcano, Gómez Jc, I. Lambarri, G. Bilbao, Iñigo Pomposo, Ofélia Adriana Hernández-Rodríguez, R. Villoria, Zarranz Jj, P Madoz, J. Garibi,
Tópico(s)Genetic Neurodegenerative Diseases
ResumoClinical outcomes of Parkinson's disease patients treated for 12 months with STN-DBS were analyzed. PATIENTS ADN METHODS: Twelve patients were selected using the CAPSIT protocol criteria and placement of electrodes in the appropriate target was performed according to results of fusion image techniques and intraoperative microrecording.A reduction in motor UPDRS (44 %) and activities of daily living (58 %) scores during > phases were observed. > time with dyskinesias was reduced (86 %), while severe dyskinesias disappeared. Levodopa dosage was also lowered (44 %). Patients and caregivers showed a clear-cut benefit on quality of life (58 % and 61 % respectively). No cognitive deterioration was observed and morbidity was in the same range as that published by other teams.Bilateral STN-DBS is an effective symptomatic therapy for complicated Parkinsońs disease patients. It improves the quality of life of patients and their caregivers and allows a reduction of levodopa dosage.
Referência(s)